M. Sellon

Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100

D. Rayson, T. Younis, C. Skedgel, 2008, Breast Cancer Research and Treatment.

Trastuzumab Beyond Progression for HER2 Positive Metastatic Breast Cancer: Progression‐Free Survival on First‐Line Therapy Predicts Overall Survival Impact

D. Rayson, T. Younis, G. Walsh, 2014, The breast journal.

Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study.

D. Rayson, T. Younis, A. Jeyakumar, 2012, Current oncology.

The cost burden of trastuzumab and bevacizumab monoclonal antibody therapy in solid tumors: Can we afford it?

D. Rayson, T. Younis, C. Skedgel, 2006, Journal of Clinical Oncology.

The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada

D. Rayson, T. Younis, C. Skedgel, 2008, Current oncology.

Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100

D. Rayson, T. Younis, C. Skedgel, 2008, Breast Cancer Research and Treatment.

Patterns of trastuzumab use and cost in a single Canadian cancer institute

D. Rayson, K. Potvin, T. Younis, 2005 .